EP4103581A1 - Antivirale wirkstoffe mit breiter aktivität - Google Patents
Antivirale wirkstoffe mit breiter aktivitätInfo
- Publication number
- EP4103581A1 EP4103581A1 EP21707155.4A EP21707155A EP4103581A1 EP 4103581 A1 EP4103581 A1 EP 4103581A1 EP 21707155 A EP21707155 A EP 21707155A EP 4103581 A1 EP4103581 A1 EP 4103581A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- branched
- cycloalkyl
- substance according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to substances with broad spectrum activity against 3C or 3C-like (3CL) proteases of RNA viruses, in particular coronaviruses, picornaviruses (especially enteroviruses) and noroviruses.
- 3CL 3C-like
- RNA viruses in particular coronaviruses, picornaviruses and noroviruses, have led to epidemics and pandemics several times in the past decades, for example the SARS coronavirus broke out in southern China in 2003 and spread to almost 30 countries around the world.
- MERS coronavirus appeared and at the beginning of 2020 the novel coronavirus SARS-CoV-2, formerly also known as 2019-nCoV.
- the 3C or 3C-like (3CL) proteases of the RNA viruses in question are seen as promising targets in the development of antiviral agents with broad spectrum activity.
- a further object of the invention is to provide new antiviral active ingredients with lung tropism.
- the object of the invention is achieved by substances of the following formula or their pharmaceutically acceptable salts and / or adducts and / or tautomers and / or solvates.
- A can be the same or different and is selected from the group consisting of N and CR 8 and where R 8 is selected from the group H, F, CI and Br and where R 1 can be identical or different and is selected from the group consisting of H, alkyl, C (0) OR 5 where R 5 can be branched or unbranched alkyl, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, arylalkyl, aryloxy, heteroalkyloxy, arylalkoxy, heteroalkylalkoxy; and C (0) NHR 6 where R 6 is branched or unbranched alkyl, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, arylalkyl, aryloxy, heteroalkyloxy, May be arylalkoxy, heteroalkylalkoxy; and SO2R 7 where R 7 can be branched or unbranched alkyl, cycloalkyl, substituted or unsub
- the object of the invention is achieved by substances of the following formula or their pharmaceutically acceptable salts and / or adducts and / or tautomers
- R 1 can be the same or different and is selected from the group consisting of H, alkyl, C (0) OR 5 where R 5 is branched or unbranched alkyl, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, arylalkyl, aryloxy, heteroalkyloxy, May be arylalkoxy, heteroalkylalkoxy; and C (0) NHR 6 where R 6 can be branched or unbranched alkyl, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, arylalkyl, aryloxy, heteroalkyloxy, arylalkoxy, heteroalkylalkoxy; and SO2R 7 where R 7 is branched or unbranched alkyl, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, arylalkyl, aryloxy, heteroalkyloxy, arylalkoxy, heteroalky
- the object of the invention is achieved by the following compounds and / or salts, adducts, tautomers, diastereomers and / or solvates of these compounds.
- the object of the invention is achieved by a substance which acts on 3C- or 3C-like (3CL) proteases of RNA viruses.
- the object of the invention is achieved by a substance which acts on the 3CL protease of the coronavirus SARS-CoV-2.
- the object of the invention is achieved by a substance which has a half-life in the plasma of more than 30 minutes, preferably more than 40 minutes, particularly preferably more than 44 minutes.
- the object of the invention is achieved by a substance which shows lung tropism.
- the lead compound designated as DZL08 for antiviral a-ketoamides, which target the 3C or 3C-like (3CL) proteases, has the following structure:
- the lead compound DZL08 was tested in virus-infected cell culture and shows good results against the enterovirus EV-A71, the Coxsackievirus B3 as well as the SARS coronavirus and the MERS coronavirus (tested in Huh-7 liver cells).
- Table 1 EC 50 values (mM) for the lead substance DZL08
- Crystallographic studies show that the ⁇ -ketoamide group in the pocket of the target protease interacts at position P1, while the amide group between P2 and P3 is essential to stabilize the complex.
- the amide group between P2 and P3 can in particular also be processed by proteases of the host cell and thus reduce the bioavailability of the desired compound.
- Figure 1 Complexation of SARS-CoV MP ro by RHCDSIe
- Figure 2 Complexation of CVB33C pro by RHCDSIe
- Figure 3 Complexation of MERS-CoV MP ro by RHCDSIe
- Figure 1 shows the complexation of the SARS coronavirus protease (SARS-CoV M pro ) by the active ingredient RHCDIe based on crystallographic studies.
- Figure 2 shows the complexation of the 3C protease of the Coxsackievirus B3 CVB33C pro by RHCDSIe.
- Figure 3 shows the complexation of the MERS coronavirus protease MERS-CoV IW 0 by RHCDSIc.
- Figure 4 shows the complexation of the 3CL protease of the coronavirus SARS-CoV-2 M pro by RHCDSIc.
- the activity of the active ingredients according to the invention in comparison to the lead substance DZL08 is particularly good for betacoronavirus proteases (SARS-CoV Mpro, MERS-CoV Mpro, SARS-CoV-2 Mpro).
- the substance RHCDSIc showed IC50 values of 0.90 ⁇ M, 0.58 ⁇ M and 0.67 ⁇ M against these proteases (the inhibition of the cleavage of a standard substrate by the active substance was measured in a fluorescence-based test). These values are slightly improved compared to those achieved with the lead substance DZL08.
- the following table 3 shows pharmacokinetic data of the compound RHCDSIe in comparison to the lead substance DZL08.
- Table 3 Pharmacokinetic data of RHCDSIe compared to DZL08
- RHCDSIe shows good metabolic stability in mouse and human microsomes. After 30 minutes, 80% of the substance remained metabolically stable in mouse microsomes and 60% in the case of human microsomes. No evidence of toxicity in mice was observed.
- Pharmacokinetic studies after subcutaneous injection of RHCDSIe in CD-1 mice (20 mg / kg) showed that the compound was only effective for about 4
- the active ingredient according to the invention can be used in medicine for the therapy of a disease. Especially for the therapy of a disease caused by RNA viruses. Especially for the therapy of a disease caused by coronaviruses, picornaviruses, including enteroviruses and / or noroviruses.
- the active ingredient according to the invention can be supplied in the form of a pharmaceutical preparation.
- the reagents and starting materials used were obtained commercially from commercial sources known to the person skilled in the art and used without further pretreatment.
- HSGF 254 silica gel plates (thickness 0.15-0.2 mm) were used for thin-layer chromatography (TLC).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020103516.0A DE102020103516B4 (de) | 2020-02-11 | 2020-02-11 | Antivirale Wirkstoffe mit breiter Aktivität |
PCT/DE2021/100129 WO2021160220A1 (de) | 2020-02-11 | 2021-02-09 | Antivirale wirkstoffe mit breiter aktivität |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4103581A1 true EP4103581A1 (de) | 2022-12-21 |
Family
ID=74672994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21707155.4A Pending EP4103581A1 (de) | 2020-02-11 | 2021-02-09 | Antivirale wirkstoffe mit breiter aktivität |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230099089A1 (de) |
EP (1) | EP4103581A1 (de) |
DE (1) | DE102020103516B4 (de) |
WO (1) | WO2021160220A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202214796D0 (en) | 2022-10-07 | 2022-11-23 | Tocris Cookson Ltd | Compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL120311A (en) | 1996-03-01 | 2001-10-31 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceuticals containing them |
CA2287569A1 (en) | 1997-05-02 | 1998-11-12 | Akzo Nobel Nv | Serine protease inhibitors |
US6906198B1 (en) * | 1998-04-30 | 2005-06-14 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds, their preparation and use |
WO2004101781A1 (en) | 2003-05-13 | 2004-11-25 | Universität Zu Lübeck | Crystal structure of human coronavirus 229e main proteinase, and uses thereof for developing sars inhibitors |
US9309284B2 (en) | 2012-05-02 | 2016-04-12 | Kansas State University Reasearch Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses |
RU2017112739A (ru) | 2014-09-17 | 2018-10-17 | Версеон Корпорейшн | Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз |
-
2020
- 2020-02-11 DE DE102020103516.0A patent/DE102020103516B4/de active Active
-
2021
- 2021-02-09 US US17/798,346 patent/US20230099089A1/en active Pending
- 2021-02-09 WO PCT/DE2021/100129 patent/WO2021160220A1/de unknown
- 2021-02-09 EP EP21707155.4A patent/EP4103581A1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
DE102020103516B4 (de) | 2023-12-07 |
US20230099089A1 (en) | 2023-03-30 |
DE102020103516A1 (de) | 2021-08-12 |
WO2021160220A1 (de) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69718177T2 (de) | Substituierte pyrimidinderivate und ihre pharmazeutische anwendung | |
EP0707006B1 (de) | Aroyl-piperidin-Derivate | |
DE60003025T2 (de) | Arylsulfonyle als faktor xa inhibitoren | |
DE69637040T2 (de) | Derivate monocyclischer Polyamine, ihre Herstellung und ihre Verwendung als antivirale Mittel | |
DE602004009426T2 (de) | Kalziumkanalblocker mit zwei benzhydril-teilen | |
DE19519245C2 (de) | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
DE69929669T2 (de) | Zyklische Amidderivate die Cathepsin K hemmen | |
DE69319351T2 (de) | Hydroxyethylaminosulfamidsäure-derivate verwendbar als inhibitoren retroviraler proteasen | |
DE69809782T2 (de) | Npy antagonisten | |
DE10121003A1 (de) | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen | |
DE3814549A1 (de) | N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln | |
DE4213919A1 (de) | Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE69332770T2 (de) | Sulfonylalkanoylaminohydroxyethylaminosulfamidsäuren verwendbar als retrovirale Proteasehemmer | |
EP0505868A2 (de) | N-Acyl-alpha-aminosäurederivate | |
WO1993004035A1 (de) | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel | |
DE2846251C2 (de) | ||
CH637130A5 (de) | Chinazolin-derivate, verfahren zu ihrer herstellung und verwendung dieser derivate in arzneimitteln. | |
EP0110073A1 (de) | Verfahren zur Herstellung von Tetrahydropyridinen | |
EP1939195A1 (de) | Neue Indolderivate und deren Verwendung als Arzneimittel | |
EP0509354B1 (de) | Aminosäurederivate | |
EP4103581A1 (de) | Antivirale wirkstoffe mit breiter aktivität | |
DE60209806T2 (de) | 2-amino-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase | |
DE69233255T2 (de) | Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen | |
DE2941288C2 (de) | ||
DE69635798T2 (de) | 4-aminotetrahydrobenzisoxazole oder -isothiazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220902 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230913 |